IPF-ITV-2

IPF-ITV-2 is an investigational therapeutic derived from Immunotech Laboratories’ inactivated pepsin fraction (IPF) platform and appears to be a follow‑on or variant to the earlier ITV-2 preparation that was planned for clinical testing in patients with chronic viral infections such as HIV/AIDS and idiopathic pulmonary fibrosis–related conditions. Publicly available information links it only to Immunotech’s broader IPF/ITV vaccine-like biologics, which are proposed to modulate immune responses against chronic viral infection, but detailed composition, precise mechanism of action, target biology, and formal development status have not been disclosed in the scientific or regulatory literature.[11][13][15]